Adaptive Biotechnologies (ADPT) Expected to Release Quarterly Earnings on Wednesday

Adaptive Biotechnologies (NASDAQ:ADPT) will likely be releasing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Adaptive Biotechnologies to announce earnings of ($0.13) per share and revenue of $65.4360 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same period in the prior year, the firm earned ($0.20) EPS. The business’s revenue was up 35.1% on a year-over-year basis. On average, analysts expect Adaptive Biotechnologies to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $22.58 on Wednesday. The company has a market cap of $3.61 billion, a PE ratio of -68.42 and a beta of 2.07. The firm has a fifty day moving average price of $17.94 and a two-hundred day moving average price of $16.30. Adaptive Biotechnologies has a fifty-two week low of $9.96 and a fifty-two week high of $23.15.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 386,240 shares of Adaptive Biotechnologies stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the sale, the insider directly owned 1,019,658 shares of the company’s stock, valued at approximately $22,442,672.58. The trade was a 27.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total value of $198,000.00. Following the completion of the sale, the insider owned 416,775 shares in the company, valued at approximately $7,501,950. This represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 851,484 shares of company stock valued at $17,588,045. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently modified their holdings of ADPT. T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies in the fourth quarter valued at $51,000. Strive Financial Group LLC acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $52,000. Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies during the first quarter valued at $93,000. Persistent Asset Partners Ltd bought a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at $109,000. Finally, Quadrant Capital Group LLC acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at $133,000. Institutional investors own 99.17% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday. JPMorgan Chase & Co. cut their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, July 15th. Finally, Morgan Stanley lifted their price target on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.